Exousia Pro Settles Litigation, Eliminates Debt and Shares

Got story updates? Submit your updates here. ›

Exousia Pro, Inc., a clinical-stage biotechnology company, has announced the successful settlement of outstanding litigation involving a former director. This landmark agreement will result in significant debt reduction, the cancellation of over 6 million shares, and enhanced financial transparency - all of which are expected to strengthen the company's balance sheet and increase shareholder value.

Why it matters

The resolution of this legal dispute allows Exousia Pro to focus fully on advancing its core clinical pipeline and telehealth initiatives without the distraction or financial burden of ongoing litigation. The debt elimination and share cancellation are expected to improve the company's financial position and increase the equity value, earnings potential, and ownership percentage for current shareholders.

The details

Under the settlement terms, Exousia Pro will make a one-time payment of $147,500 to the involved parties. In exchange, the company will cancel a $200,000 promissory note and the remaining balance on a note tied to preferred stock, eliminating significant liabilities. Additionally, 6,297,511 shares of common stock will be canceled and returned to treasury, reversing prior dilution and directly increasing the equity value and ownership percentage for existing shareholders.

• The settlement is expected to close within 30 days.
• The financial impacts will be recorded under GAAP in the company's upcoming financial reporting and audits.

What’s next

The judge will decide within 30 days whether to approve the settlement and allow the financial restructuring to be finalized.